Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects strong financial guidance, optimistic product development projections, and a strategic shareholder return plan. Despite some uncertainties in the Q&A, such as unclear patient growth sources for OCREVUS and lack of updates on certain products, the overall sentiment remains positive due to increased guidance, strong royalty contributions, and potential new partnerships. The stock is likely to experience a positive movement, with the potential for further upside if new deals materialize.
Key Financial Performance
Royalty Revenue $236 million, representing a 52% increase year-over-year. This growth was driven by the continued momentum of three established blockbuster subcutaneous therapies: DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo.
Total Revenue $354 million, representing 22% growth year-over-year. This was driven by the strong performance of the ENHANZE drug delivery technology and the three blockbuster therapies.
Adjusted EBITDA $248 million, reflecting a 35% increase year-over-year. This growth showcases the leverage of the high-margin royalty-driven model.
DARZALEX Sales $3.7 billion, a 20% increase year-over-year. Growth was driven by strong share gains across all lines of therapy and market growth.
Phesgo Revenue CHF 1.8 billion (~$2.3 billion), reflecting a 54% year-over-year increase. Growth was driven by increasing conversion from intravenous Perjeta and Herceptin to Phesgo.
VYVGART Sales $1.13 billion, a 96% year-over-year increase. Growth was driven by the subcutaneous formulation enabled by ENHANZE, which expanded access to new prescribers and patients.
OCREVUS Revenue CHF 5.2 billion (~$6.5 billion) for the first 9 months of 2025, up 7% year-over-year. Growth was driven by the subcutaneous formulation, which offers a rapid 10-minute injection and expands access to underserved patient populations.
Tecentriq Revenue CHF 2.6 billion (~$3.3 billion) for the first 9 months of 2025. Growth was driven by the subcutaneous formulation, which offers a more convenient 7-minute injection.
OPDIVO Sales $2.5 billion in Q3 2025, reflecting a 6% year-over-year increase. Growth was driven by the U.S. launch of OPDIVO Qvantig with ENHANZE, which offers a 3- to 5-minute subcutaneous administration.
RYBREVANT Revenue $198 million in Q3 2025, reflecting triple-digit year-over-year growth. Growth was driven by the subcutaneous formulation with ENHANZE, which simplifies treatment and enhances patient convenience.
Cash, Cash Equivalents, and Marketable Securities $702 million as of September 30, 2025, compared to $596.1 million on December 31, 2024. The increase was driven by cash generated from operations, offset by share repurchases.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ENHANZE drug delivery technology: Continued to drive significant momentum in the business, enabling subcutaneous delivery of therapies that were previously administered intravenously. This technology allows treatments to be administered in minutes, improving patient convenience and reducing healthcare system burdens.
DARZALEX subcutaneous: Received European Commission approval for a new indication in smoldering multiple myeloma, expanding its reach to early-stage patients and potentially increasing treatment duration. Achieved 96% share of sales in the U.S. and over 90% globally for subcutaneous formulations, with projections to remain the gold standard for multiple myeloma treatment.
VYVDURA pre-filled syringe with ENHANZE: Approved in Japan for self-injection for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, enabling at-home administration and simplifying treatment.
Elektrofi acquisition: Acquired to expand the portfolio of drug delivery technologies, enabling higher concentration formulations for subcutaneous delivery, furthering the vision for at-home biologic therapies. Strategically acquired to enhance drug delivery capabilities, enabling higher concentration formulations and expanding the potential for at-home biologic therapies.
Phesgo: Continued to be Roche's #1 growth driver, with increasing conversion from intravenous formulations and projected peak conversion of 60%.
VYVGART Hytrulo: Expanded access to new prescribers and patients, with projections for the total addressable market to grow significantly in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Financial performance: Reported record royalty revenue of $236 million, a 52% year-over-year increase, and total revenue of $354 million, a 22% growth year-over-year.
Guidance update: Raised full-year 2025 revenue guidance to $1.3 billion-$1.375 billion, reflecting 28%-35% growth, with royalty revenue expected to grow 49%-54%.
Cash flow and balance sheet: Generated robust cash flow, repurchased $342 million in shares year-to-date, and maintained a strong balance sheet with $702 million in cash and equivalents.
Pipeline development: Progressed 8 programs in clinical development, with 2 additional programs anticipated, representing potential new royalty growth opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals and Market Expansion: The company is heavily reliant on regulatory approvals and market expansion for its growth catalysts. Delays or failures in obtaining approvals for new indications or products could adversely impact revenue projections and strategic objectives.
Supply Chain and Manufacturing: The acquisition of Elektrofi and the integration of its Hypercon technology could pose operational challenges. Any disruptions in the supply chain or manufacturing processes could delay product launches and impact financial performance.
Competitive Pressures: The company faces intense competition in the pharmaceutical and biotechnology sectors. Competitors' advancements or new product launches could erode market share and impact revenue.
Economic and Market Conditions: Economic uncertainties and market conditions could affect the adoption of the company's products, particularly in regions with limited healthcare infrastructure.
Strategic Execution Risks: The company's ambitious growth plans, including the integration of new technologies and expansion into new markets, carry execution risks. Failure to effectively manage these initiatives could impact long-term growth.
Dependence on Key Products: A significant portion of the company's revenue is derived from a few key products like DARZALEX, Phesgo, and VYVGART. Any decline in the performance of these products could materially affect financial results.
Financial Leverage: The acquisition of Elektrofi is expected to increase the company's net leverage to approximately 2x net debt-to-EBITDA. This could limit financial flexibility and increase vulnerability to economic downturns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: Halozyme has raised its full-year 2025 revenue guidance to $1.3 billion to $1.375 billion, reflecting 28% to 35% growth over 2024. Royalty revenue is expected to grow 49% to 54%, reaching $850 million to $880 million.
Adjusted EBITDA: The company anticipates adjusted EBITDA of $885 million to $935 million, representing year-over-year growth of 40% to 48%.
Non-GAAP Diluted EPS: Non-GAAP diluted earnings per share are projected to be $6.10 to $6.50, reflecting year-over-year growth of 44% to 54%.
Product Launches and Approvals: Halozyme expects two additional U.S. approvals in 2025: DARZALEX subcutaneous for smoldering multiple myeloma and RYBREVANT subcutaneous for EGFR-mutated non-small cell lung cancer.
Long-Term Revenue Streams: The company anticipates sustained royalty contributions from all products through at least 2030, with several extending into the 2040s.
Elektrofi Acquisition: The acquisition of Elektrofi is expected to enable at-home administration of biologic therapies and expand the portfolio of drug delivery technologies. The transaction is projected to be less than 5% dilutive to non-GAAP diluted EPS over the medium term, with potential milestone payments offsetting dilution before projected royalty revenues in 2030 and beyond.
Pipeline Development: Eight programs are in various stages of clinical development, with two additional programs anticipated. Advanced opportunities include Bristol-Myers Squibb's subcutaneous nivolumab with relatlimab and Takeda's TAK-881, both in Phase III development.
Market Expansion: The company projects significant growth opportunities for its blockbuster products, including DARZALEX, Phesgo, and VYVGART, which represent a $30 billion total addressable market opportunity by 2028. Newer launches also represent an additional $30 billion opportunity by 2028.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: Year-to-date, Halozyme repurchased $342 million of shares with $158 million remaining under the current authorized plan. Since 2019, the company has returned approximately $1.9 billion to shareholders through repurchases, representing greater than 100% of cumulative free cash flow over that period.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the company plan to balance paying down debt, share buybacks, and potential acquisitions like Elektrofi?
A:The company plans to continue looking for opportunities like Elektrofi while maintaining a balanced approach to capital allocation. They expect to pay down debt quickly after a modest draw on their credit facility for the Elektrofi acquisition. They have also funded $342 million in share repurchases this year and will continue this balanced approach.
Q:How can investors monitor the performance of Elektrofi going forward?
A:Investors can monitor Elektrofi's performance through three metrics: (1) the potential for two partner first-in-human starts with blockbuster products by the end of 2026, (2) streamlined development plans resulting from the collaboration, and (3) advancement of Hypercon with current partners or new deals.
Q:What is the awareness level of Elektrofi's technology among current ENHANZE partners?
A:The awareness level is good based on diligence and market research, but the deal has not closed yet, so discussions are limited. Some partners have provided feedback signaling strong support for the opportunities of working across both platforms.
Q:What is driving market growth for OCREVUS?
A:OCREVUS grew by 5,000 patients in the last quarter, with 50% of patients in the U.S. and Germany being new to the brand. However, it is unclear whether these patients are new to treatment or switching from other therapies. The growth is attributed to expanded access in physician offices and community hospitals.
Q:What is the company's approach to M&A and leveraging for transactions?
A:The company is focused on completing the Elektrofi acquisition and is unlikely to pursue another acquisition this year. They are willing to go up to 3x net leverage for the right opportunity but will maintain a patient and thoughtful approach to M&A.
Q:When might feasibility studies for combining ENHANZE with Hypercon be conducted?
A:Feasibility studies for combining ENHANZE with Hypercon will be an early conversation between technical experts from both companies after the acquisition closes. However, the initial focus will be on pursuing each technology separately.
Q:What is the potential for new ENHANZE deals in the near term?
A:The company is confident about signing a new ENHANZE deal this year, with several discussions ongoing. They are excited about the continued interest in ENHANZE.
Q:Which products contributed the most to the guidance upside this quarter?
A:The guidance upside was driven by strong royalties from VYVGART Hytrulo, Phesgo, and DARZALEX, with new indications for DARZALEX and VYVGART Hytrulo contributing to the growth.
Q:How is the company thinking about maintaining growth into 2026 and beyond?
A:The company is tracking to exceed 2025 expectations and will provide more details in early 2026. They are confident in their ability to maintain growth due to strong momentum and input from partners.
Q:How is the company conducting outreach for prospective partners between ENHANZE and Hypercon?
A:Until the HSR review is completed, the two businesses are operating separately and pursuing their own conversations and targeted outreach. ENHANZE focuses on larger volume delivery, while Hypercon targets smaller volume, at-home delivery.
Q:What is the development path and economics for the auto-injector business?
A:The small-volume auto-injectors are ready for immediate integration, while high-volume auto-injectors are clinic-ready and can be integrated into development plans. The small-volume auto-injectors follow a cost model, while high-volume auto-injectors are associated with royalties and a cost per device.
Q:When can updates on the ViiV and Acumen products be expected?
A:There have been no recent updates from ViiV or Acumen. The last update from Acumen indicated the completion of Phase I testing. Further updates will depend on public disclosures from these partners.
Q:How does the company plan to drive revenue growth into the next decade, especially as key product contracts terminate?
A:The company plans to sustain growth through three waves: (1) current blockbusters like DARZALEX and VYVGART with new indications, (2) recently launched products like OCREVUS and OPDIVO, and (3) a development pipeline with products launching before and after 2028. New deals signed now could launch in the early 2030s, adding new royalty streams.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on where OCREVUS patients are coming from (new to treatment or switching therapies). They also did not provide updates on the ViiV and Acumen products beyond previously disclosed information. Additionally, they did not specify the timeline for feasibility studies combining ENHANZE with Hypercon, only stating it would be an early conversation post-acquisition.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CHF month
Commission approval
DARZALEX European
ENHANZE technology
European Commission
Hypercon technology
OCREVUS
OPDIVO
Phase III
RYBREVANT
Slide driver
VYVGART
access
acquisition transaction
beginning curve
community practice
contribution product
conversion launch
core ENHANZE
delivery opportunity
delivery technology
development program
driver DARZALEX
franchise
gMG CIDP
health care
hospital infusion
landscape
launch opportunity
momentum
neurology
profile
provider
self injection
solution
stage
syringe ENHANZE
therapy DARZALEX
value
HALO Transcript
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Positive5-11
The earnings call indicates strong financial performance with 80% YoY growth, promising product pipeline, and strategic partnerships. The Q&A section highlights management's confidence in scalability and future launches, despite some lack of specificity. The guidance reflects robust revenue projections, and the absence of negative financial surprises suggests a positive market reaction.
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Neutral3-11
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
HALO Slides
HALO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
